Recipharm partners with CanVirex to advance oncolytic virus therapy
· Recipharm and CanVirex have signed a strategic manufacturing development collaboration supporting the clinical development of CanVirex's oncolytic measles virus platform · The programme will establish a scalable manufacturing process for CanVirex's lead candidate, expressing IL-12, targeting advanced solid tumours · …
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Conapto secures new bridge facility
- Mandatory Notification of Trade of Primary Insiders
- BTC AB redeems approximately 5 percent of the B shares for SEK 4.7 million at SEK 121.43 per share, a 28 percent discount to NAV
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →